Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Aimovig (erenumab-aooe by Year
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Amgen Aimovig (erenumab-aooe: $311M in FY2025, up 1.0% from a year earlier.
Where the FY2025 figure comes from
“|| Aimovig — U.S. | 311 | 1 | % | 308 | 2 | % | 303”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 311 | +1.0% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 308 | +1.7% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 303 | -23.9% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 398 | +27.2% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 313 | -17.2% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 378 | +23.5% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 306 | +157.1% | Form 10-K (amgn-12312019x10kq42019.htm, filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 119 | – | Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Aimovig (erenumab-aooe ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-aimovig-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.